Pharmacokinetics of amphotericin B in children
- PMID: 2610508
- PMCID: PMC172800
- DOI: 10.1128/AAC.33.11.1989
Pharmacokinetics of amphotericin B in children
Abstract
Amphotericin B is the most effective agent for the majority of systemic fungal infections but often causes toxicity, and specific dosage guidelines for amphotericin B in pediatric patients are lacking. The purpose of this study was to characterize the pharmacokinetics of amphotericin B in children. Twelve patients (mean age, 6.6 years; range, 4 months to 14 years) receiving amphotericin B, 0.68 +/- 0.34 mg/kg per day (mean plus or minus standard deviation), were studied. Four to eight blood samples were collected during a 24-h period and analyzed by high-pressure liquid chromatography. The peak concentration of amphotericin B in serum was 2.9 +/- 2.8 micrograms/ml. The mean total clearance, apparent volume of distribution, and elimination half-life were 0.46 +/- 0.20 ml/min per kg, 0.76 +/- 0.52 liters/kg, and 18.1 +/- 6.6 h, respectively. Total clearance decreased with age (p less than 0.01). In children aged 8 months to 9 years, the mean total clearance was 0.57 +/- 0.15 ml/min per kg, and in children older than 9 years, it was 0.24 +/- 0.02 ml/min per kg. Interpatient variation in the clearance and volume of distribution of amphotericin B was greater than threefold and greater than eightfold, respectively. However, pharmacokinetic parameters did not change in two stable patients who were studied again. Because clearance decreased substantially with age, older children may require lower doses of amphotericin B per kilogram to decrease the potential for toxicity.
Similar articles
-
Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.Antimicrob Agents Chemother. 1996 Mar;40(3):609-12. doi: 10.1128/AAC.40.3.609. Antimicrob Agents Chemother. 1996. PMID: 8851579 Free PMC article. Clinical Trial.
-
Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.Antimicrob Agents Chemother. 2017 Jan 24;61(2):e01477-16. doi: 10.1128/AAC.01477-16. Print 2017 Feb. Antimicrob Agents Chemother. 2017. PMID: 27855062 Free PMC article. Clinical Trial.
-
Pharmacokinetics and adverse effects of amphotericin B in infants and children.J Pediatr. 1988 Sep;113(3):559-63. doi: 10.1016/s0022-3476(88)80653-x. J Pediatr. 1988. PMID: 3411404
-
[Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story].Rev Esp Quimioter. 2012 Mar;25(1):17-24. Rev Esp Quimioter. 2012. PMID: 22488537 Review. Spanish.
-
Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children.Clin Microbiol Infect. 2001;7 Suppl 2:68-79. doi: 10.1111/j.1469-0691.2001.tb00012.x. Clin Microbiol Infect. 2001. PMID: 11525221 Review.
Cited by
-
Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.Antimicrob Agents Chemother. 1997 Sep;41(9):1944-8. doi: 10.1128/AAC.41.9.1944. Antimicrob Agents Chemother. 1997. PMID: 9303390 Free PMC article. Clinical Trial.
-
Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.Antimicrob Agents Chemother. 1999 Jun;43(6):1417-23. doi: 10.1128/AAC.43.6.1417. Antimicrob Agents Chemother. 1999. PMID: 10348763 Free PMC article. Clinical Trial.
-
Flow cytometric assay for estimating fungicidal activity of amphotericin B in human serum.Med Microbiol Immunol. 1992;181(3):117-26. doi: 10.1007/BF00202051. Med Microbiol Immunol. 1992. PMID: 1522821
-
Human pharmacogenomic variations and their implications for antifungal efficacy.Clin Microbiol Rev. 2006 Oct;19(4):763-87. doi: 10.1128/CMR.00059-05. Clin Microbiol Rev. 2006. PMID: 17041143 Free PMC article. Review.
-
Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor.Clin Pharmacokinet. 2010 Jul;49(7):479-92. doi: 10.2165/11531830-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20528008
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources